By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verona Pharma 

Suite 21 - Alpha House
100 Borough High Street
London    SE1 1LB  United Kingdom
Phone: 44-0-20-7863-3300 Fax: 44-0-20-7863-3314



Life Sciences

Company News
Verona Pharma (VRP.L) Data Demonstrating PDE3/4 Inhibitor RPL554 Enhances CTFR-Dependent Currents In Cystic Fibrosis Airway Epithelia 10/8/2015 10:17:09 AM
Verona Pharma (VRP.L) Positive Headline Data From RPL554 Clinical Study In COPD Patients 9/29/2015 9:36:04 AM
Verona Pharma (VRP.L) Appoints Dr Ken Cunningham And Dr Anders Ullman As Non-Executive Directors 9/8/2015 10:51:28 AM
Verona Pharma (VRP.L) Release: Interim Results For The Six Months Ended 30 June 2015 9/8/2015 10:46:49 AM
Verona Pharma (VRP.L) Release: Secondary Listing To Provide Trading Facility On Xetra Exchange In Germany 6/12/2015 8:58:33 AM
Verona Pharma (VRP.L) Release: RPL554 Phase 2a Trial Started; Headline Data Expected Q1 2016 6/11/2015 9:23:13 AM
Verona Pharma (VRP.L) Release: RPL554 MAD Study In Healthy Volunteers Confirms Excellent Tolerability; Dosing Of COPD Patients Commences 6/8/2015 9:16:09 AM
Verona Pharma (VRP.L) Release; RPL554 Presentation At The Asthma And COPD Conference, London, 14 April 2015 4/14/2015 9:44:19 AM
Verona Pharma (VRP.L) Release: Trading and Development Programme Update 3/3/2015 7:44:58 AM
Verona Pharma (VRP.L) Release: First Patients Successfully Dosed In Clinical Trial With New Commercially Scalable Formulation Of Nebulised RPL554 1/12/2015 11:16:10 AM